Evidence map›Paper›PMID 37466791›Full record

ArticleJournal of cancer research and clinical oncology2023

Impact of encorafenib on survival of patients with BRAF

M Zurloh, M Goetz, T Herold, J Treckmann, P Markus, B Schumacher, D Albers, A Rink, V Rosery, G Zaun and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

M ZurlohDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
M GoetzWest German Cancer Center, Institute of Pathology Essen, University Hospital Essen, Essen, Germany.
T HeroldWest German Cancer Center, Institute of Pathology Essen, University Hospital Essen, Essen, Germany.
J TreckmannWest German Cancer Center, Department of General, Visceral and Transplant Surgery, University Hospital Essen, Essen, Germany.
P MarkusDepartment of General Surgery and Traumatology, Elisabeth Hospital, Essen, Germany.
B SchumacherDepartment of Gastroenterology, Elisabeth Hospital, Essen, Germany.
D AlbersDepartment of Gastroenterology, Elisabeth Hospital, Essen, Germany.
A RinkWest German Cancer Center, Department of General, Visceral and Transplant Surgery, University Hospital Essen, Essen, Germany.
V RoseryDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
G ZaunDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
K KostbadeDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
M PogorzelskiDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
S TingWest German Cancer Center, Institute of Pathology Essen, University Hospital Essen, Essen, Germany.
H SchmidtDepartment of Gastroenterology, Hepatology and Transplant Medicine, University Hospital Essen, Essen, Germany.
R StiensDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
M WieswegDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
M SchulerDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
Stefan KasperDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany. stefan.kasper-virchow@uk-essen.de.
I VirchowDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePatients with BRAF PATIENTS AND

methodsClinico-pathological data were extracted from the electronic health records. Kaplan-Meier method was used to estimate overall (OS) and progression-free survival (PFS). Objective response rate (ORR) was assessed according to RECIST 1.1.

resultsIn total, 51 patients were enrolled. FOLFOXIRI was administered to 12 patients; 29 patients received FOLFOX or FOLFIRI as first-line treatment. Median OS was 17.6 months. Median PFS with FOLFOXIRI (13.0 months) was significantly prolonged (HR 0.325) as compared to FOLFOX/FOLFIRI (4.3 months). However, this failed to translate into an OS benefit (p = 0.433). Interestingly, addition of a monoclonal antibody to chemotherapy associated with superior OS (HR 0.523). A total of 64.7% patients received further-line therapy, which included a BRAF inhibitor in 17 patients. Targeted therapy associated with very favourable OS (25.1 months).

conclusionPatients with BRAF

Indexed as

CarbamatesColorectal NeoplasmsProto-Oncogene Proteins B-rafSulfonamidesAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCamptothecinFemaleFluorouracilHumansLeucovorinMaleMiddle AgedMutationBRAF protein, humanCamptothecinCarbamatesencorafenibFluorouracilLeucovorinOrganoplatinum CompoundsProto-Oncogene Proteins B-rafSulfonamidesBRAFV600EChemotherapyEncorafenibMetastatic colorectal cancer

Identifiers

PMID37466791
PMCPMC10587317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.